aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma, a clinical stage biotechnology company, announced its participation in three investor conferences in September 2024. These include the Wells Fargo Healthcare Conference on September 5 in Everett, MA (1x1 investor meetings), the H.C. Wainwright 26th Annual Global Investment Conference on September 11 in New York, NY (corporate presentation at 10:30am EDT), and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York, NY (corporate presentation at 1:55pm EDT).
Webcasts of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on aTyr's website for at least 90 days. The company's management will also be available for one-on-one meetings with registered conference attendees. aTyr focuses on developing therapies for fibrosis and inflammation using tRNA synthetase biology, with their lead candidate efzofitimod targeting interstitial lung disease.
aTyr Pharma, un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione a tre conferenze per investitori a settembre 2024. Queste includono la Wells Fargo Healthcare Conference il 5 settembre a Everett, MA (incontri individuali con gli investitori), la H.C. Wainwright 26th Annual Global Investment Conference l'11 settembre a New York, NY (presentazione aziendale alle 10:30 EDT), e la Cantor Fitzgerald Global Healthcare Conference il 18 settembre a New York, NY (presentazione aziendale alle 13:55 EDT).
I webcast delle presentazioni di H.C. Wainwright e Cantor Fitzgerald saranno disponibili sul sito web di aTyr per almeno 90 giorni. La gestione dell'azienda sarà inoltre disponibile per incontri individuali con i partecipanti registrati alla conferenza. aTyr si concentra sullo sviluppo di terapie per la fibrosi e l'infiammazione utilizzando la biologia della sintesi dell'tRNA, con il loro principale candidato efzofitimod mirato alla malattia polmonare interstiziale.
aTyr Pharma, una compañía biotecnológica en etapa clínica, anunció su participación en tres conferencias para inversores en septiembre de 2024. Estas incluyen la Wells Fargo Healthcare Conference el 5 de septiembre en Everett, MA (reuniones uno a uno con inversores), la H.C. Wainwright 26th Annual Global Investment Conference el 11 de septiembre en Nueva York, NY (presentación corporativa a las 10:30 EDT), y la Cantor Fitzgerald Global Healthcare Conference el 18 de septiembre en Nueva York, NY (presentación corporativa a la 1:55 EDT).
Las transmisiones en vivo de las presentaciones de H.C. Wainwright y Cantor Fitzgerald estarán disponibles en el sitio web de aTyr durante al menos 90 días. La dirección de la compañía también estará disponible para reuniones uno a uno con los asistentes registrados para la conferencia. aTyr se enfoca en desarrollar terapias para la fibrosis y la inflamación utilizando la biología de la sintesis de tRNA, con su candidato principal efzofitimod dirigido a la enfermedad pulmonar intersticial.
aTyr Pharma는 임상 단계의 생명공학 회사로, 2024년 9월에 열리는 세 개의 투자자 회의에 참여한다고 발표했습니다. 회의에는 9월 5일 매사추세츠주 에버렛에서 열리는 웰스 파고 헬스케어 컨퍼런스 (1대1 투자자 회의), 9월 11일 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스 (오전 10:30 EDT 기업 발표), 9월 18일 뉴욕에서 열리는 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스 (오후 1:55 EDT 기업 발표)가 포함됩니다.
H.C. 웨인라이트와 칸토르 피츠제럴드 발표의 웹캐스트는 aTyr의 웹사이트에서 최소 90일 동안 제공될 예정입니다. 회사 관리자는 등록된 회의 참석자와 1대1 회의도 가능합니다. aTyr는 tRNA 합성 효소 생물학을 활용하여 섬유증 및 염증 치료제를 개발하는 데 집중하며, 주 후보물질인 efzofitimod는 간질성 폐질환을 목표로 하고 있습니다.
aTyr Pharma, une entreprise de biotechnologie en phase clinique, a annoncé sa participation à trois conférences pour investisseurs en septembre 2024. Cela inclut la Wells Fargo Healthcare Conference le 5 septembre à Everett, MA (réunions individuelles avec les investisseurs), la H.C. Wainwright 26th Annual Global Investment Conference le 11 septembre à New York, NY (présentation de l'entreprise à 10h30 EDT), et la Cantor Fitzgerald Global Healthcare Conference le 18 septembre à New York, NY (présentation de l'entreprise à 13h55 EDT).
Les webdiffusions des présentations de H.C. Wainwright et de Cantor Fitzgerald seront disponibles sur le site web d'aTyr pendant au moins 90 jours. La direction de l'entreprise sera également disponible pour des réunions individuelles avec les participants enregistrés à la conférence. aTyr se concentre sur le développement de thérapies pour la fibrose et l'inflammation en utilisant la biologie de la synthèse de l'tRNA, avec leur principal candidat efzofitimod ciblant la maladie pulmonaire interstitielle.
aTyr Pharma, ein Unternehmen der Biotechnologie in der klinischen Phase, hat seine Teilnahme an drei Investorenkonferenzen im September 2024 angekündigt. Dazu gehören die Wells Fargo Healthcare Conference am 5. September in Everett, MA (1x1 Investorenmeetings), die H.C. Wainwright 26th Annual Global Investment Conference am 11. September in New York, NY (Unternehmenspräsentation um 10:30 Uhr EDT) und die Cantor Fitzgerald Global Healthcare Conference am 18. September in New York, NY (Unternehmenspräsentation um 13:55 Uhr EDT).
Webcasts der Präsentationen von H.C. Wainwright und Cantor Fitzgerald werden mindestens 90 Tage lang auf der Website von aTyr verfügbar sein. Das Management des Unternehmens wird ebenfalls für persönliche Meetings mit registrierten Konferenzteilnehmern zur Verfügung stehen. aTyr konzentriert sich auf die Entwicklung von Therapien gegen Fibrose und Entzündungen unter Verwendung der tRNA-Synthetase-Biologie, wobei der Hauptkandidat efzofitimod auf interstitielle Lungenerkrankungen abzielt.
- None.
- None.
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024.
Details of the conferences appear below:
Conference: Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2024
Location: Everett, MA
Format: 1x1 Investor Meetings
Conference: H.C. Wainwright 26th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 10:30am EDT
Location: New York, NY
Format: Corporate Presentation
Conference: Cantor Fitzgerald Global Healthcare Conference
Date: Wednesday, September 18, 2024
Time: 1:55pm EDT
Location: New York, NY
Format: Corporate Presentation
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ
What investor conferences will aTyr Pharma (ATYR) attend in September 2024?
When and where will aTyr Pharma (ATYR) present at the H.C. Wainwright conference?
Will aTyr Pharma (ATYR) provide webcasts of their September 2024 conference presentations?
What is aTyr Pharma's (ATYR) lead therapeutic candidate?
What is the focus of aTyr Pharma's (ATYR) research and development?
